Curon Medical Expands Stretta Procedure to European Marketplace

Apr 26, 2001, 01:00 ET from Curon Medical, Inc.

    SUNNYVALE, Calif., April 26 /PRNewswire/ --
 Curon Medical, Inc. (Nasdaq:   CURN) today announced that the first commercial
 Stretta System(TM) procedures have been successfully completed in Europe.  The
 procedures were performed by Dr. Chris B. Feretis at the Hygeia Hospital in
 Athens, Greece.  Dr. David Utley, Chief Medical Officer of Curon Medical was
 present during the cases and provided the initial training for the physician.
 Additionally, four sites, based at the University Hospital of Bologna, Italy,
 University Hospital Leuven, Belgium, University Hospital Munich, and HSK
 Klinikum Wiesbaden, in Germany, received training on the Stretta System and
 have begun to treat patients as part of a trial focused on developing support
 for reimbursement of the procedure in these countries.
     "The overwhelming response from the physicians has been the ease of the
 procedure itself and the positive outcomes seen in our clinical trials,"
 stated Dr. David Utley, Chief Medical Officer of Curon Medical.  "We are
 pleased by the acceptance of this novel procedure and anticipate continued
 growth of physician training and patient cases in Europe through the multiple
 "Centers of Excellence."
     Based on the success of the treatments, each center has agreed to become a
 "Center of Excellence" for patient care in providing the Stretta Procedure.
 The facilities holding this status will meet a number of requirements
 including continued physician training opportunities, serving as a regional
 referral point for patients seeking the Stretta Procedure, and producing
 original research to further develop the procedure.
     "My colleagues and I found the Stretta Procedure to be a strong treatment
 option for those patients who suffered from chronic heartburn," stated Dr.
 Chris B. Feretis, from the Hygeia Hospital in Athens, Greece; the first
 physician to perform commercial cases in Europe.  "The Stretta Procedure, as
 performed in the United States, has demonstrated successful patient outcomes
 over the past year and we are looking forward to continuing this trend here in
 Europe."
 
     About Curon Medical, Inc.
     Curon Medical, Inc. of Sunnyvale, Calif., develops, manufactures and
 markets innovative proprietary products for the treatment of gastrointestinal
 disorders.  The company's products consist of radiofrequency generators and
 single-use disposable devices.  Its first product, the Stretta System,
 received United States Food and Drug Administration clearance in April 2000
 for the treatment of gastroesophageal reflux disease, commonly referred to as
 GERD.  For more information, please visit the Company's Web site at
 http://www.curonmedical.com.
 
     Safe Harbor Statement
     This news release contains forward-looking statements about Curon Medical,
 Inc., which are based on current expectations that involve risks and
 uncertainties.  Curon Medical's actual results may differ from the results
 described in the forward-looking statement.  Factors that could cause actual
 results to differ include, but are not limited to our inability to obtain
 follow-up data on the Stretta System randomized control study, longer term
 clinical data failing to support data collected to date, and delays in the
 completion of the U.S. multi-center clinical trial of the Secca System.  These
 and other risk factors are detailed in Curon Medical's periodic reports and
 registration statements filed with the Securities and Exchange Commission.
 
     Contacts:
 
     John W. Morgan                     Media Relations:
     President and CEO                  Kesinee Yip
     Curon Medical, Inc.                Noonan/Russo Communications
     (408) 733-9910                     (415) 677-4455, ext. 244
     jmorgan@curonmedical.com           k.yip@noonanrusso.com
 
     Alistair F. McLaren                Investor Relations:
     Vice President, CFO                Ana Kapor
     Curon Medical, Inc.                Noonan/Russo Communications
     (408) 733-9910                     (415) 677-4455, ext. 207
     amclaren@curonmedical.com          a.kapor@noonanrusso.com
 
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X38876113
 
 

SOURCE Curon Medical, Inc.
    SUNNYVALE, Calif., April 26 /PRNewswire/ --
 Curon Medical, Inc. (Nasdaq:   CURN) today announced that the first commercial
 Stretta System(TM) procedures have been successfully completed in Europe.  The
 procedures were performed by Dr. Chris B. Feretis at the Hygeia Hospital in
 Athens, Greece.  Dr. David Utley, Chief Medical Officer of Curon Medical was
 present during the cases and provided the initial training for the physician.
 Additionally, four sites, based at the University Hospital of Bologna, Italy,
 University Hospital Leuven, Belgium, University Hospital Munich, and HSK
 Klinikum Wiesbaden, in Germany, received training on the Stretta System and
 have begun to treat patients as part of a trial focused on developing support
 for reimbursement of the procedure in these countries.
     "The overwhelming response from the physicians has been the ease of the
 procedure itself and the positive outcomes seen in our clinical trials,"
 stated Dr. David Utley, Chief Medical Officer of Curon Medical.  "We are
 pleased by the acceptance of this novel procedure and anticipate continued
 growth of physician training and patient cases in Europe through the multiple
 "Centers of Excellence."
     Based on the success of the treatments, each center has agreed to become a
 "Center of Excellence" for patient care in providing the Stretta Procedure.
 The facilities holding this status will meet a number of requirements
 including continued physician training opportunities, serving as a regional
 referral point for patients seeking the Stretta Procedure, and producing
 original research to further develop the procedure.
     "My colleagues and I found the Stretta Procedure to be a strong treatment
 option for those patients who suffered from chronic heartburn," stated Dr.
 Chris B. Feretis, from the Hygeia Hospital in Athens, Greece; the first
 physician to perform commercial cases in Europe.  "The Stretta Procedure, as
 performed in the United States, has demonstrated successful patient outcomes
 over the past year and we are looking forward to continuing this trend here in
 Europe."
 
     About Curon Medical, Inc.
     Curon Medical, Inc. of Sunnyvale, Calif., develops, manufactures and
 markets innovative proprietary products for the treatment of gastrointestinal
 disorders.  The company's products consist of radiofrequency generators and
 single-use disposable devices.  Its first product, the Stretta System,
 received United States Food and Drug Administration clearance in April 2000
 for the treatment of gastroesophageal reflux disease, commonly referred to as
 GERD.  For more information, please visit the Company's Web site at
 http://www.curonmedical.com.
 
     Safe Harbor Statement
     This news release contains forward-looking statements about Curon Medical,
 Inc., which are based on current expectations that involve risks and
 uncertainties.  Curon Medical's actual results may differ from the results
 described in the forward-looking statement.  Factors that could cause actual
 results to differ include, but are not limited to our inability to obtain
 follow-up data on the Stretta System randomized control study, longer term
 clinical data failing to support data collected to date, and delays in the
 completion of the U.S. multi-center clinical trial of the Secca System.  These
 and other risk factors are detailed in Curon Medical's periodic reports and
 registration statements filed with the Securities and Exchange Commission.
 
     Contacts:
 
     John W. Morgan                     Media Relations:
     President and CEO                  Kesinee Yip
     Curon Medical, Inc.                Noonan/Russo Communications
     (408) 733-9910                     (415) 677-4455, ext. 244
     jmorgan@curonmedical.com           k.yip@noonanrusso.com
 
     Alistair F. McLaren                Investor Relations:
     Vice President, CFO                Ana Kapor
     Curon Medical, Inc.                Noonan/Russo Communications
     (408) 733-9910                     (415) 677-4455, ext. 207
     amclaren@curonmedical.com          a.kapor@noonanrusso.com
 
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X38876113
 
 SOURCE  Curon Medical, Inc.